FDA revokes its authorization of hydroxychloroquine to treat coronavirus

4 months ago 35
google news

By Matthew Perrone The Associated Press

Posted June 15, 2020 12:26 pm

3:47 New study finds controversial malaria drug ineffective against COVID-19

After a months-long trial, researchers from across North America – including at the MUHC – have determined that hydroxychloroquine is ineffective at preventing COVID-19. Dr. Emily McDonald joins Global’s Laura Casella.

The U.S. Food and Drug Administration is revoking its emergency authorization for malaria drugs promoted by President Donald Trump for treating COVID-19 amid growing evidence they don’t work and could cause deadly side effects.

The agency said Monday that the drugs hydroxychloroquine and chloroquine are unlikely to be effective in treating the coronavirus. Citing reports of heart complications, the FDA said the drugs pose a greater risk to patients than any potential benefits.

The decades-old drugs, also prescribed for lupus and rheumatoid arthritis, can cause heart rhythm problems, severely low blood pressure and muscle or nerve damage.

[ Sign up for our Health IQ newsletter for the latest coronavirus updates ]

The move means that shipments of the drugs obtained by the federal government will no longer be distributed to state and local health authorities. The drugs are still available for alternate uses, so U.S. doctors could still prescribe them for COVID-19 — a practice known as off-label prescribing.

Story continues below advertisement

On Thursday, a National Institutes of Health expert panel revised its guidelines to specifically recommend against the drug’s use except in formal studies.

Trump aggressively pushed the drug beginning in the first weeks of the outbreak and stunned medical professionals when he revealed he took the drug preemptively against infection.

View link »

© 2020 The Canadian Press

  1. Homepage
  2. Health